These example sentences are selected automatically from various online news sources to reflect current usage of the word ‘human immunodeficiency virus.’ Views expressed in the examples do not represent the opinion of Merriam-Webster or its editors. Send us feedback.
Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol. 1995 Nov. 69(11):6859-64. [Medline]. [Full Text].
ABC can cause a hypersensitivity reaction during the first two to six weeks of therapy in approximately 5% of individuals. The hypersensitivity reaction most often causes fever and other symptoms, such as muscle aches, nausea, diarrhea, rash, or cough. The symptoms generally get worse with each dose of ABC and, if suspected, therapy must be discontinued and never restarted for fear of developing a life-threatening reaction. There is now a simple blood test (HLA-B*5701) that can be performed to determine whether a patient is at risk for developing the hypersensitivity reaction. If the test is positive, the patient should never receive this medication. There is also conflicting data stating that abacavir may or may not be associated with increased risk of cardiovascular events.
There are many drugs currently in development that may simplify therapy and provide important options for those who have developed extensive drug resistance. Drugs that show promise in early clinical trials are often made available by the manufacturer to certain individuals with approval of the FDA. In particular, these drugs are used in individuals who are no longer responding or able to tolerate currently available agents. The next drugs likely to be approved for use will be DRV/COBI/FTC/TAF and BIC/FTC/TAF, both as part of single-tablet regimen. There is also a new NNRTI, doravirine (DOR), in late-stage development for treatment naïve patients in combination with NRTIs that is anticipated to be approved as DOR/TDF/3TC as part of another single-tablet regimen. Novel treatment strategies are also being pursued in the form of a long-acting injectable formulation or RPV in development along with a long-acting new InSTI called cabotegravir (CAB). An early stage study showed that the combination of short-acting RPV and CAB was able to maintain virologic suppression in those with suppressed viral load. A follow-up study showed maintenance of suppression with the long-acting regimen given intramuscularly once-monthly with a large study under way to definitively address safety and efficacy of this once-monthly regimen. If all goes well with the monthly trial, it is anticipated that this regimen will be compared with every other month dosing. Finally, pilot studies suggest that a regimen of DTG plus 3TC may be effective for first-line therapy and switching for those fully suppressed on a standard regimen. Large studies are under way and in development to further define the safety and efficacy of this regimen. Other drugs in earlier stages of development would include new agents in new classes that either block viral maturation of attachment to the cell.
Ecchymotic purple-brownish macule and a 1-cm nodule on the dorsum of the hand of a 65-year-old male of Ashkenazi-Jewish extraction. See a picture of Kaposi’s Sarcoma Ecchymotic and learn more about the health topic.
When HIV infection is advanced, either through treatment failure or in untreated infection, and has caused immune system destruction, secondary infections (opportunistic infections) can occur. Using other antiviral drugs and antibiotics to prevent secondary infection may prevent severe illness and premature (early) death.
Because viral reproduction is almost completely carried out by host cell mechanisms, there are few points in the process where stopping viral reproduction will not also kill host cells. For this reason there are no chemotherapeutic agents for most viral diseases. acyclovir is an antiviral that requires viral proteins to become active. Some viral infections can be prevented by vaccination (active immunization), and others can be treated by passive immunization with immune globulin, although this has been shown to be effective against only a few dozen viruses.
The source is qualified by whether it is known or unknown. If the source is unknown (eg, a needle on the street or in a sharps disposal container), risk should be assessed on the circumstances of the exposure (eg, whether the exposure occurred in an area where injection drug use is prevalent, whether a needle discarded in a drug-treatment facility was used). If the source is known but HIV status is not, the source is assessed for HIV risk factors, and prophylaxis is considered (see Table: Postexposure Prophylaxis Recommendations).
Both HIV-1 and HIV-2 are believed to have originated in non-human primates in West-central Africa, and are believed to have transferred to humans (a process known as zoonosis) in the early 20th century.
When HIV grows (that is, by reproducing itself), it acquires the ability to change (mutate) its own structure. These mutations enable the virus to become resistant to previously effective drug therapy.
simian-human immunodeficiency virus a chimeric, engineered virus with the envelope of human immunodeficiency virus and the cytoplasm and nucleus of simian immunodeficiency virus; it is used in animal models because it is a better mimic of HIV than SIV is.
The number of persons with undiagnosed HIV infection was estimated by subtracting the number of reported cumulative diagnoses from the number of estimated cumulative infections. The percentage of undiagnosed infections was determined by dividing the number of undiagnosed infections by the total HIV prevalence. [redirect url=’http://penetratearticles.info/bump’ sec=’7′]